- Home
- GVH vs INDP Comparison
GVH vs INDP Comparison
Compare GVH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- INDP
- Stock Information
- Founded
- GVH 2016
- INDP 2000
- Country
- GVH Australia
- INDP United States
- Employees
- GVH N/A
- INDP N/A
- Industry
- GVH
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- GVH
- INDP Health Care
- Exchange
- GVH Nasdaq
- INDP Nasdaq
- Market Cap
- GVH 7.4M
- INDP 7.4M
- IPO Year
- GVH 2023
- INDP N/A
- Fundamental
- Price
- GVH $0.49
- INDP $0.50
- Analyst Decision
- GVH
- INDP Strong Buy
- Analyst Count
- GVH 0
- INDP 2
- Target Price
- GVH N/A
- INDP $8.50
- AVG Volume (30 Days)
- GVH 123.4K
- INDP 75.0K
- Earning Date
- GVH 02-12-2025
- INDP 05-07-2025
- Dividend Yield
- GVH N/A
- INDP N/A
- EPS Growth
- GVH 12.04
- INDP N/A
- EPS
- GVH 0.09
- INDP N/A
- Revenue
- GVH $16,540,178.00
- INDP N/A
- Revenue This Year
- GVH N/A
- INDP N/A
- Revenue Next Year
- GVH N/A
- INDP N/A
- P/E Ratio
- GVH $5.22
- INDP N/A
- Revenue Growth
- GVH N/A
- INDP N/A
- 52 Week Low
- GVH $0.47
- INDP $0.43
- 52 Week High
- GVH $2.57
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- GVH 36.55
- INDP 39.50
- Support Level
- GVH $0.49
- INDP $0.45
- Resistance Level
- GVH $0.50
- INDP $0.53
- Average True Range (ATR)
- GVH 0.04
- INDP 0.04
- MACD
- GVH 0.00
- INDP 0.01
- Stochastic Oscillator
- GVH 14.73
- INDP 66.67
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.